openPR Logo
Press release

Deep Brain Stimulation Devices Market

Transparency Market Research (TMR) has published a new report, titled “Deep Brain Stimulation Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”.The report states that the global deep brain stimulation devices market for Parkinson’s disease will expand at a CAGR of 11.0% during the forecast period from 2013 to 2019. In 2012, the global deep brain stimulation devices market for Parkinson’s disease was worth US$4.5 bn and by 2019, it is projected to be worth US$9.4 bn.

Download Complete Healthcare Analytical Brochure: : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1435

According to The Parkinson’s Disease Foundation, there are around 10 million people around the world suffering from this condition and more than 1 million of these people are living in America. The global deep brain stimulation devices market for Parkinson’s disease is driven by the expanding geriatric population and the high prevalence of neurological conditions such as Alzheimer’s disease, dementia, and Parkinson’s disease.

In addition to this, the global deep brain stimulation devices market for Parkinson’s disease will be driven by the rising demand for deep brain stimulation (DBS) devices due to the increasing popularity of minimally invasive procedures. DBS surgical therapy is currently the therapy of choice during the advanced stages of the Parkinson’s disease. On the other hand, chemotherapy is recommended generally during the early stages of the disease. Medical practitioners and patients are increasingly choosing DBS over drug therapy as the latter is considered to have several side effects. Furthermore, the efficacy of drug therapy cannot be gauged accurately.

Moreover, the favorable reimbursement scenario is also adding to the growing acceptance of these devices worldwide. The global deep brain stimulation devices market for Parkinson’s disease will also benefit from the rising availability of innovative deep brain stimulation devices.

On the other hand, the global deep brain stimulation devices market for Parkinson’s disease will be challenged by the risks associated with deep brain stimulation procedures. Furthermore, the implementation of certain policies from the government such as the Affordable Care Act in the U.S. will restrict the global deep brain stimulation devices market for Parkinson’s disease.

Research Report: http://www.transparencymarketresearch.com/deep-brain-stimulator-market.html

Players in the global deep brain stimulation devices market for Parkinson’s disease will benefit from the opportunity provided by the high unmet needs in the emerging economies located in Asia Pacific and other regions. Regionlly, the global deep brain stimulation devices market for Parkinson’s disease is segmented into North America, Asia Pacific, Europe, and Rest of the World.

The global deep brain stimulation devices market for Parkinson’s disease is led by a handful of players. These include: Boston Scientific Corporation, Aleva Neurotherapeutics SA, St. Jude Medical, Inc., and Medtronic, Inc. The research study states that companies by focusing on improving public awareness regarding the disease, related consequences and treatment options can greatly benefit by expanding their reach. Furthermore, hiring CMOs for manufacturing deep brain stimulation devices will also help companies to boost their revenue. Another recommendation from the report is for companies to focus on enhanced product life and reducing prices of DBS devices to create better prospects.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deep Brain Stimulation Devices Market here

News-ID: 351556 • Views: 271

More Releases for Parkinson’s

Parkinson’s Disease Therapeutic Market- Trends, Outlook 2025
Parkinson’s disease (PD) is a chronic disorder characterized by the malfunctioning and death of vital nerve cells in the brain, and can be characterized by tremor, dementia, and depression. Parkinson’s disease progression leads to uncontrolled body movement of the patient. There is no cure presently for parkinson’s disease only treatments options such as medication and surgery to manage the symptoms are available. Parkinson’s disease mainly affects people over 50 and
Parkinson’s disease Therapeutics Parkinson’s disease Therapeutics Market to …
This report studies the global Parkinson's Disease Therapeutics market, analyzes and researches the Parkinson's Disease Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like GSK Novartis Boehringer Ingelheim Teva Pharmaceutical Abbvie ….. Ask for sample copy @ https://www.researchtrades.com/request-sample/1199125 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment by Type, Parkinson's Disease Therapeutics can be split into Medications Therapeutics Medical Devices Therapeutics Buy
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds
Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that
Parkinson’s Disease - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Parkinson’s Disease - Heat Map and Analysis to its growing collection of premium market research reports. Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties,
New Education Options for Parkinson’s Caregivers
(4/30/2012- Gilbert, Ariz.) When a loved one is diagnosed with Parkinson’s Disease (PD), it becomes clear that Parkinson’s is a life- changing experience for the entire family — particularly for the primary care provider, who is most often a spouse, child or parent. Family caregivers may not think of themselves as a care providers or recognize their new caregiving tasks. As family members begin helping with doctor visits, taking over financial